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Introduction
Amputation and limb loss are prevalent across the United States. Approximately 2
million people currently struggle due to limb loss in the United States and the numbers are rising
(Amputee Coalition, 2017). The major causes for amputations are vascular diseases, such as
diabetes, which make up 54% of amputations, and trauma, which makes up 45% of amputations.
Approximately 2% of amputations are due to cancer (Amputee Coalition, 2017). Among the
amputee population, as many as 85% experience some type of phantom limb pain (PLP)
(Nikolajsen & Christensen, 2015). Among veterans with amputations, approximately 73%
experience some form of PLP (Balakhanlou, 2020).
PLP was identified by Ambrose Pare, a French military surgeon, in the sixteenth century,
and was further described by Silas Weir Mitchell in the nineteenth century (Subedi & Grossberg,
2011). PLP is a neuropathic pain described as the pain experienced in a missing limb after
amputation (Collins et al., 2018). Neuropathic pain is extremely common in the United States,
and is estimated to cost more than $600 billion a year to treat (Kuffler, 2018). According to
Kuffler, women are more likely to develop PLP, as well as upper extremity amputees and those
experiencing stump pain (Kuffler, 2018; Dijkstra et al., 2002). PLP can be debilitating, and can
drastically affect the quality of life of those who experience it. It is often described as cramping,
stabbing, electric shock, burning, and clenching sensations (Collins et al., 2018; Mayo Clinic,
2021). For some amputees PLP is constantly present, while for others it is more sporadic and
comes in waves (Collins et al., 2018). Further, the pain serves as a constant reminder of the
incident that led to their limb loss (Trevelyan et al., 2015).
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Understanding the underlying cause of PLP is an essential component in attempting to
treat the condition. The theories that explain why PLP occurs are discussed in further detail in
the sections titled “Cortical Reorganization Theory” and “Proprioceptive Memory,” however, are
briefly discussed in the following paragraphs.
While the exact etiology is not certain, there are many theories about why and how this
phenomenon occurs. One of the most widely accepted theories of the cause of PLP is cortical
reorganization of the somatosensory cortex, known as the cortical reorganization theory (CRT),
in which the area of the brain responsible for interpreting sensory information undergoes
structural change (Collins et al., 2018).
Another possible cause for PLP is proprioceptive memory. Memories kept in the part of
the brain responsible for storing information about the limb that was amputated, the cerebellum
and the brainstem, can possibly contribute to PLP, as the brain is able to store memories of the
limb in order to perform tasks more quickly, without using visual feedback (Collins et al., 2018;
Anderson-Barnes et al., 2009; “Proprioception: Additional Information,” 2014). Further research
needs to be done in order to find evidence that supports these hypotheses.
While there is no single treatment that is universally effective for PLP, a significant
number of therapies have been proposed and proven to help many amputees. One of the most
widely used and accepted treatments is mirror therapy (MT) (Collins et al., 2018). When a mirror
is placed next to the intact limb, and the missing limb is placed behind the mirror, the brain
receives visual feedback that the missing limb is intact and moving without pain. This tricks the
brain into thinking that the missing limb is in fact present, which has been shown to drastically
reduce the prevalence of PLP (Collins et al., 2018). While this therapy does not work for all
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amputees, it has had promising results, as PLP can be alleviated when the brain perceives the
missing limb as present.
Another treatment for PLP is the use of pharmaceuticals. For example, gabapentin is an
anticonvulsant drug often used for treatment of seizures, and has been shown to decrease pain in
some patients experiencing PLP (Yasaei et al., 2021). Morphine, an analgesic opioid, has also
shown an ability to reduce pain in patients with PLP (Murphy et al., 2021). While these drugs
have shown some promise, very little research has been done to fully understand the efficacy of
these drugs to treat PLP, especially when compared to the wealth of studies looking at phantom
limb pain.
Phantom limb pain is a phenomenon that many people suffer from post-amputation which
greatly affects their quality of life. PLP is important to study so that we may improve the lives of
all impacted amputees. Amputees experience severe trauma from the amputation itself, therefore
anything that can be done to alleviate PLP after the amputation is essential to increase amputees’
quality of life and allow them to get back to their everyday lives. While there are many studies
examining the efficacy of mirror therapy and pharmaceuticals to address PLP individually, little
has been done to compare the two treatments directly. This review addresses the gap in the field
by comparing the efficacy of MT treatment to pharmaceutical treatment of phantom limb pain.

Cortical Reorganization Theory
The exact etiology, or cause of PLP is unknown, yet there are many promising theories
regarding its possible cause. One of the most posited theories is the cortical reorganization theory
(CRT), which occurs in the central nervous system. This theory posits that the somatosensory
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cortex undergoes a sort of rewiring, therefore altering the organization of the neuronal network.
The somatosensory cortex is the part of the brain that is responsible for interpreting somatic
sensory information, such as the sense of touch, and is often referred to as the sensory
homunculus. It is located on the postcentral gyrus of the parietal lobe of the brain (Nguyen &
Duong, 2021). The human body is said to be “mapped” in this cortex, as it contains a faithful
representation of the human body. Different regions of the somatosensory cortex receive sensory
input from different parts of the body, and thus, the cortex is an essential aspect of sensations felt
throughout the entire body. After an amputation, this cortex can undergo reorganization, which is
believed to play a role in PLP. The human brain is extremely plastic, meaning that it is constantly
adapting to its environment and reworking its neuronal pathways (Andoh et al., 2018). While this
is a normal phenomenon in the human brain, injury can result in maladaptive cortical plasticity,
in which the neuronal pathways are altered in an abnormal way that can result in pain in the
phantom limb. The somatosensory cortex is responsible for the sensory input of the brain and
contains a map of the entire body. Therefore, when part of the body is removed, that part of the
cortex is no longer active, and leaves it susceptible to invasion from other parts of the
somatosensory cortex, possibly contributing to PLP (Collins et al., 2018). Vilayanur
Ramachandran, M.D., a prominent neuroscientist, tested this hypothesis with a man by the name
of D. S. (Rawlence, 2001). D. S. lost his left arm to an amputation and began experiencing
severe PLP. He explained that his phantom hand felt as though it was extremely clenched, and he
could not unclench it. This brought him excruciating pain, and he was unsure how to fix this.
Ramachandran took interest in D. S.’s situation and began to meet with him to try to understand
what was causing him this pain. Upon talking with D. S., Ramachandran found out that he felt
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the presence of his phantom limb when the left side of his face was touched. This led
Ramachandran to perform a brain scan on Steen in hopes of seeing a visual representation of the
phenomenon. When Steen was wired to the scan technology, Ramachandran would touch
different parts of D. S.’s body, and compare that to the part of his brain that was activated. When
he touched the left side of D. S.’s face, the scan showed brain activity in both the left face region
of the cortex and the left arm region of the cortex. This showed that the map of the left side of
the face had merged into the inactive region of the left arm, potentially explaining why D. S. felt
the presence of his phantom limb (Rawlence, 2001; Ramachandran & Hirstein, 1998). While this
study only dealt with one person experiencing PLP, it was a promising study that provided
evidence to support the CRT.
This theory was further supported by a study performed in 1998. In this study,
neuromagnetic source imaging (MSI) was used to analyze cortical reorganization in five
congenital and five traumatic amputees without PLP, and four traumatic amputees experiencing
PLP (Flor et al., 1998). MSI is a way in which the structure of the brain is mapped out using the
magnetic fields of the brain (“Magnetic Source Imaging,” 1996; What is Magnetic Source
Imaging, 2021). A shift in the somatosensory cortex was measured using the magnetic field and
magnetic resonance imaging (MRI) (“Magnetic Source Imaging,” 1996). Traumatic amputees
experiencing PLP showed the most reorganization, with a 2.22 cm shift in the somatosensory
cortex (Flor et al., 1998), while congenital and traumatic amputees not experiencing PLP saw
little to no reorganization. A shift is characterized by the amount of the cortex that was invaded
by the neighboring region during stimulation of the mouth. Although a small study, it shows the
correlation between cortical reorganization and PLP.
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Proprioceptive Memory
Another theory concerning the etiology of PLP is proprioceptive memory. Proprioception
is the perception of the body in space and allows for the human body to perform both simple and
complex tasks (Anderson-Barnes et al., 2009). For example, our proprioception allows us to ride
a bike, despite our focus being on the road ahead, rather than on the pedals. Our brain has a
memory of where our feet are, and therefore we do not need visual feedback in order to pedal a
bike (Anderson-Barnes et al., 2009).
The brain still has a memory of where the limb should be, despite it having been
removed. Many amputees describe their phantom limb as being in the same position it was in
just prior to the amputation, or even in the position it was in during the traumatic event resulting
in amputation (Anderson-Barnes, 2009). Gentili and colleagues’ study of phantom limb
sensations in amputees who received a brachial plexus block found that a significant number of
patients felt the position of their phantom limb after the plexus was related to the position of the
phantom limb before the plexus (Gentili et al., 2002). This further demonstrates that
proprioception may have a significant role in the cause of PLP. More research is necessary to
determine the exact relationship of PLP and proprioceptive memories.
Pain memories are also related to proprioception. These are memories that the brain holds
after the body experiences painful stimuli and acts as a protective mechanism in order to prevent
the body from repeating those stimuli (Anderson-Barnes et al., 2009). An example of a pain
memory is the pain experienced from overextending a finger. The brain processes the pain felt in
the finger, sending a motor response to the finger to move it. The finger is then moved back to a
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normal position in order to alleviate the pain (Anderson-Barnes et al., 2009). Mirror therapy
(MT) provides visual feedback of the limb to the brain, which allows the brain to process the
limb as though it were intact. This can alleviate PLP in some cases, as the disconnect between
the limb and the brain is lessened, and the pain memories can be cleared (Anderson-Barnes et al.,
2009). There is insufficient evidence linking pharmaceuticals to proprioceptive memory. While
this theory is regarded as one of the major causes of PLP, it is not exactly known how these
proprioceptive and pain memories result in pain experienced in the phantom limb.

Methodology for Composing the Thesis
While there are other treatments that have shown a reduction in PLP, such as
acupuncture, MT and pharmaceuticals were focused on in this literature review. Mirror therapy is
one of the most common treatments for PLP, and has shown to consistently cause a decrease in
PLP. Morphine is widely prescribed and used for the treatment of pain, and studies have shown
its possible efficacy for the treatment of PLP. Gabapentin is another pharmaceutical often used
for the treatment of epilepsy and neuropathic pain, and has recently been studied in regards to the
treatment of PLP. While there are other pharmaceuticals that have been used for the treatment of
PLP, such as ketamine and lidocaine, morphine and gabapentin were examined in this literature
review (Mayo Clinic, 2021).
Studies were examined from the 1990s through 2021, and used the Visual Analogue
Scale and the Short Form McGill Pain Questionnaire. The studies were compared based on the
trends reported for the decrease of PLP, as well as the percent of participants that reported a
decrease in PLP.
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Mirror Therapy
As discussed above, V.S. Ramachandran was a prominent figure in studying PLP. While
determining that the possible cause of PLP was the invasion of the inactive region of the
somatosensory cortex by active regions of the cortex, he decided to try to create some sort of
treatment for this debilitating phenomenon (Rawlence, 2001). Ramachandran recognized that
phantom limbs lacked the visual feedback that our present limbs provide our brain, and knowing
this, he created a therapy called the mirror box. The mirror box is a box that had a mirror placed
vertically in the middle of it and was open on the top and front. The amputee puts their intact
limb and residual limb in the box on either side of the mirror and sees the reflection of their
intact limb moving (Fig. 1). In studies using MT, this often translates to a reduction of PLP, as
the visual feedback from the mirror tricks the brain into thinking the phantom limb is present,
and moving freely without pain (Guenther, 2016).
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Figure 1. Mirror therapy with a leg amputee performed at the Naval Medical Center San Diego.
A) This image shows the reflection of the intact limb, while the amputated limb is behind the
mirror. B) This image shows the amputated limb on the outside of the mirror (Hanling et al.,
2010).

The exact mechanisms as to how MT works are not known, however, there are theories
that explain the possible mechanisms behind this treatment. After amputation there is a
disconnect between the physical and mental representation of the body (Collins et al., 2018).
Although the physical limb is no longer present, the somatosensory cortex within the brain still
has the representation of the limb. Ramachandran explains this phenomenon through the brain’s
positive feedback loops (Rawlence, 2001; Ramachandran et al., 1995). When an amputee is
experiencing PLP or a state of paralysis of the phantom limb, the brain keeps sending signals to
the phantom limb, and is unable to stop as there is no visual feedback to show the brain that the
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limb is in a painful or clenched state. This positive feedback loop can be interrupted by using the
mirror box. By putting the intact and phantom limb inside the mirror box, the reflected image of
the intact limb allows the brain to receive visual feedback. It is believed that the brain then
receives these visual signals that the limb is intact and freely moving, which stops those clenched
signals from being sent to the phantom limb (Rawlence, 2001; Ramachandran et al., 1995).
While this treatment does not work for all amputees, it provides many with relief.

Mirror Therapy Efficacy
In 1996, Ramachandran and Rogers performed a study to test the efficacy of MT on
amputees experiencing the presence of a phantom limb (Ramachandran &
Rogers-Ramachandran, 1996). This was the first study that tested the effect of visual feedback on
phantom limbs. In this study, ten upper limb amputees with differing levels of amputation
participated in MT, most of whom experienced either PLP or improper movement of their
phantom limb, such as paralysis (Ramachandran & Rogers-Ramachandran, 1996). They were
asked to mirror their limb movements while looking at the mirror, and then asked to close their
eyes and try to do the same thing. The procedure that was followed varied from participant to
participant, however, the results showed the promising efficacy of MT (Ramachandran &
Rogers-Ramachandran, 1996). Six of the ten participants were able to voluntarily move their
phantom limb when using the mirror box, while four participants found the mirror to be no help.
Of the five participants that experienced the clenching of their phantom hand, four were able to
unclench it with the presence of the mirror (Ramachandran & Hirstein, 1998).
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In a 2017 study, 64 amputees experiencing PLP were evaluated before and after using
MT, and 52 of the amputees were soldiers or ex-servicemen (Ramadugu et al., 2017). MT was
performed for 15 minutes a day every day of the week for a period of four weeks. The study used
the Short Form McGill Pain Questionnaire (SF-MPQ), which provides a comprehensive analysis
of individuals experiencing severe pain (“The McGill Pain Questionnaire,” 2021) (Fig. 2).
Ramadugu’s study shows a significant decrease in the overall PLP experienced by the
participants, from a mean baseline SF-MPQ score of 3.65 to a mean of 0.15 after the 16th week
of the study. The control group exhibited a decrease in the mean score, from 2.37 to 0.33,
however, this was not a significant difference (Ramadugu et al., 2017).

Figure 2. This is the Short Form McGill Pain Questionnaire. The fifteen pain descriptors
are located on the left side of the form, with ratings from zero to three for each descriptor. This
scale takes approximately five minutes to complete, and is a simple way to analyze the patient’s
pain (“Short-form McGill Pain Questionnaire,” 2021; Niere, 2009).

14
An analysis of two studies was done in 2017, where there was a significant decrease in
PLP after MT was used (Griffin et al., 2017). MT was practiced by 33 amputees for 15 minutes a
day for five days a week, over a four-week period. PLP was determined using the 100 cm visual
analogue scale (VAS) (Fig. 3). The initial average VAS score was between 40 and 50, and the
average VAS score at the end of the treatment was between 10 and 20. Those with the highest
baseline pain, 60 or above on the VAS, experienced the most relief after 21 sessions, those with
median pain, 30-60 on the VAS, found relief at 14 sessions, and those with the lowest pain, 0-30
on the VAS, found relief at 7 sessions (Griffin et al., 2017). This trend indicates that the higher
the baseline PLP, the more time it takes to reduce PLP using MT. On average, the highest
baseline pain group found a decrease in pain from the 60-70 range to the 30-40 range on the
VAS. The median baseline pain group found an average decrease in pain from the 30-35 range to
the 0-15 range. The lowest baseline pain group found an average decrease in pain of 15-20 range
to the 0-5 range (Griffin et al., 2017).

Figure 3. 100 cm Visual Analogue Scale (Research Gate, 2021). This scale is a simple way to
measure pain experienced by a patient, and provides more specificity than the 10 cm VAS.
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In 2013, Foell and colleagues performed a study with 13 upper limb amputees with at
least weekly PLP (Foell et al., 2013). During the study, participants performed MT daily, and
gave daily reports of pain using the 100 cm Visual Analogue Scale (VAS). This began with two
weeks of baseline pain ratings without MT, then a four week phase of MT, and concluded with
another two week phase with no MT. The results of this study showed that there was a significant
decrease, 27% decrease, in PLP throughout the MT period (Foell et al., 2013). At week 1, the
average pain level on the VAS was a 28.21, and at week 8 it was 23.44. It was also shown
through MRI that the somatosensory cortex in the hemisphere responsible for the phantom
sensations resembled that of the intact limb’s somatosensory cortex, showing that cortical
reorganization is likely a factor in PLP (Foell et al., 2013).
Finn and colleagues in 2017 organized a study with 15 upper extremity amputees (Finn et
al., 2017). The participants were divided into three groups: the control, where MT was performed
with a covered mirror, the mental visualization therapy, where participants were asked to perform
mental visualization exercises, and the mirror therapy group. MT was performed five days a
week for 15 minutes a day, over a four week period. The 100 cm VAS was used to rate the pain
experienced by the participants, which decreased from an average of 41.4 at the beginning of the
study to a 27.5 at the end of the study. Eight out of the nine amputees in the MT group
experienced a decrease in PLP after MT was performed for four weeks (Finn et al., 2017).

Pharmaceutical Treatment
While MT is the most studied treatment for PLP, recent research has shown the possible
efficacy of using pharmaceuticals to treat PLP. There are a wide variety of drugs that have been
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used to alleviate PLP, including ketamine, lidocaine, and antidepressants (Alviar et al., 2016). In
this literature review, the efficacy of morphine and gabapentin in treating PLP was analyzed.
Morphine is an opioid that is widely used to relieve pain. Gabapentin is known for its use to treat
nerve pain, and is more of a novel treatment when it comes to PLP. One such pharmaceutical is
morphine, which is an opioid analgesic, or a pain reliever. Opioids are a class of drugs that are
often used as pain relievers. They bind opioid receptors in the brain as well as throughout the
body, and block pain signals from reaching the brain (“What are Opioids,” 2021). Morphine
activates the opioid receptors in the brain, which in turn activates inhibitory pathways of the
central nervous system (CNS) and afferent, or sensory, neurons of the PNS (Fig. 4) (Murphy et
al., 2021). This decreases the activity of afferent neurons, which may contribute to a decrease in
PLP. Morphine is typically administered either intravenously at 2.5 to 10 milligrams, or
subcutaneously at 5 to 20 milligrams (“Morphine Sulfate,” 2020).
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Figure 4. The opioid receptor is binding morphine, inhibiting the release of GABA,
which typically inhibits the release of dopamine. However, when GABA is inhibited, dopamine
is released (“Pain and Progress,” 2014).

Gabepentin has also been proposed as a possible treatment for PLP. Gabapentin is an
anticonvulsant drug often used to treat epilepsy and nerve pain. It inhibits excitatory
neurotransmitters by binding tovoltage-gated calcium channels, which can contribute to the
decrease in pain (Yasaei et al., 2021). For the treatment of neuropathic pain, gabapentin is often
administered at 300 to 1200 mg three times a day (Yasaei et al., 2021)
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Figure 5. Transmission of the neurotransmitter GABA with and without gabapentin present. A)
Without gabapentin present, GABA is free to bind the receptors on the receiving neuron. B) With
gabapentin present, gabapentin binds the receptors on the receiving neuron, and reduces the
release of GABA (“What are the Signs,” 2020).

Efficacy of Pharmaceuticals
In 2001, Huse and colleagues performed a double-blind crossover study to test the
efficacy of morphine sulfate (MST) in the treatment of PLP (Huse et al., 2001). Twelve unilateral
amputees took part in the study, where they were evaluated for four weeks without any
treatment, followed by a four-week phase where participants were administered either MST or a
glucose placebo in the form of a pill once daily. A 1-2 week washout phase was completed,
followed by another four week treatment phase where the participants received the treatment
they did not have previously. Throughout the study, pain intensity was documented hourly using
a 10 cm visual analogue scale (VAS) (Fig. 5). The results showed that there was a significant
decrease in PLP during the MST treatment phases compared with both the baseline and placebo
phases, with a baseline VAS rating of 4.65 to a 3.26 during the MST phase, to a 1.54 by the
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second follow up twelve months later. It was found that 42% of the participants were responders
to MST, meaning more than a 50% decrease in pain occurred. The long-term effects of MST
were analyzed in nine of the twelve participants, which included follow ups six and twelve
months after the 12-week study. Of the nine participants, 44% were responders at the six-month
follow-up, and 55% at the twelve-month follow-up (Huse et al., 2001).

Figure 5. 10 cm Visual Analogue Scale. (“Visual Analogue Scale,” 2021). This scale is a
simple way to measure the pain experienced by a patient.

This study also shows the changes in cortical reorganization that occurs in response to
MST treatment. Some participants with a higher amount of pain at the baseline showed a
significant decrease in cortical reorganization with MST treatment, while participants with a
lower amount of pain at the baseline showed less cortical reorganization (Huse et al., 2001). This
shows that morphine can work to reorganize the somatosensory cortex in a way that reduces PLP.
Since cortical reorganization likely contributes to PLP, it makes sense that the reduction of this
reorganization would limit pain.
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Another double-blind crossover study was performed by Wu and colleagues in 2002,
comparing the effects of morphine and lidocaine on PLP and stump pain (Wu et al., 2002). This
study recruited 31 amputees to participate, nine of which experienced only PLP, and eleven of
which had both stump and phantom pain. The participants either received morphine, lidocaine, or
the placebo intravenously. Pain was measured every five minutes using a 100 cm VAS and began
30 minutes before the infusion. When participants received morphine, a 0.05 mg/kg bolus was
administered over two minutes, followed by a 0.2 mg/kg infusion over 40 minutes. The same
procedure was followed for the lidocaine and placebo, but dosing was slightly different. The
results of this study showed that morphine significantly reduced both stump pain and PLP when
compared to the placebo (Wu et al., 2002). PLP decreased on the 100 point VAS from the start of
the infusion to after the infusion. While exact numbers were not given, PLP reduced from about
the 40-50 range on the VAS to the 30-40 range on average across patients. (Wu et al., 2002).
In 2015, Kumar and others performed a case study on an individual to determine the
efficacy of long-term high-dose morphine on PLP (Kumar et al., 2015). This individual was a
72-year-old male who had a leg amputation due to a malignant tumor in his tibia. He was given a
3 mg epidural of morphine for five days to alleviate post-operative pain, which was effective. He
was prescribed 5 mg of oral morphine to be taken every four hours. A week later he complained
of PLP, which was an 8 on the VAS, and was prescribed 10 mg of morphine, which was
gradually increased to 120 mg over a month’s time. This stable dose decreased his pain to a 1-3
on the VAS, which was maintained for one year. He then began to experience an increase in his
PLP, and his morphine dose was increased to 300 mg four hourly, which lowered his pain to
below a 4 on the VAS. His pain increased again, and an epidural analgesia and bupivacaine
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infusion were administered, alleviating more pain, which decreased his pain rating to a 4 on the
VAS. The study reported that any time oral morphine was weaned, PLP increased. Once again,
his pain began to increase, and the oral morphine dose was increased to 540 mg every four hours,
which maintained a decrease in PLP, rated below a 4 on the VAS (Kumar, et al., 2015).
A study performed in 2000 showed gabapentin to be an effective treatment for PLP
(Bone, 2002). This was a double-blind crossover study with 19 amputees who had experienced
PLP for at least six months prior to the study. Their PLP had to be at least a 40 out of 100 on the
VAS to be included in the study. There were two six-week phases with a one-week washout
period where participants were either administered gabapentin or the placebo. The dose of
gabapentin started at 300 mg a day in the form of a tablet, and was slowly increased to the
highest dose tolerated, or 2,400 mg. Pain was measured on the VAS and recorded daily, however,
the values were not reported. The results showed that gabapentin did not cause a significant
decrease in PLP during the first five weeks, however, did show a significant pain decrease in the
sixth week (Bone, 2002).
In 2005, a double-blind crossover study was performed with 24 participants to show the
efficacy of gabapentin in treating residual limb pain (RLP) and PLP (Smith et al., 2005). The
participants either received gabapentin or the placebo for six weeks; their pain was measured on
the VAS and the Short Form McGill Pain Questionnaire. Participants receiving gabapentin were
administered 300 mg to start and titrated up by 300 mg to the highest tolerable dose, or 3,600 mg
maximum. There was no significant decrease in PLP pain between the gabapentin and placebo
groups, however, the authors reported that over half of the participants reported a “meaningful
decrease” in PLP (Smith et al., 2005).
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In 2006, Nikolajsen and colleagues performed a study on the effects of gabapentin on
post-amputation pain over a six-month period, where there was no significant difference between
the placebo and gabapentin groups (Nikolajsen et al., 2006). In this study, 46 amputees
participated, and were randomly assigned to the placebo or gabapentin treatment group. Those
who received gabapentin started at 300 mg a day and were slowly titrated up to 2,400 mg a day
over the course of a month. Pain intensity was measured nightly on the VAS. The McGill Pain
Questionnaire was also used to assess pain. Neither the VAS nor the McGill Pain Questionnaire
showed a significant difference of PLP between the gabapentin and placebo groups. The values
of pain rating were not reported (Nikolajsen et al., 2006).

Comparing the Efficacy of MT and Pharmaceuticals
Five MT studies, three morphine studies, and three gabapentin studies were examined to
determine the efficacy of each treatment for PLP. It is important to compare each study and
treatment in order for both physicians and patients to make informed decisions about what course
of action to take to get the greatest relief of PLP.
Of the MT studies, four of the five showed a significant decrease in PLP on either the
SF-MPQ or the VAS. Ramachandran & Roger’s 1996 study reported that many participants
improved mobility and decreased PLP with MT, however, pain was not rated on a numerical
scale (Ramachandran & Rogers-Ramachandran, 1996). Ramadugu and Finn’s studies reported
that 89% of participants experienced a decrease in PLP, and Griffin’s study reported an 87%
decrease (Ramadugu et al., 2017; Finn et al., 2017; Griffin et al., 2017). Foell’s study found that
38% of the participants reported a significant decrease in PLP (Foell et al., 2013).
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The SF-MPQ was only used in Ramadugu’s study for MT, and reported a decrease in
PLP (Ramadugu et al., 2017). Griffin, Foell, and Finn’s studies used either the 10 cm or 100 cm
VAS, and all reported a decrease in PLP as well (Griffin et al., 2017; Foell et al., 2013; Finn et
al., 2017).
The three morphine studies showed a significant decrease in PLP, while one gabapentin
study demonstrated a meaningful decrease in PLP for some of the participants. Huse’s study
reported that 42% of the participants were clinically significant responders to MST, meaning
they found a significant decrease in PLP. In Smith’s study, 54.2% of the participants reported a
decrease in PLP. The rest of the pharmaceutical studies did not report the percent of participants
that felt a decrease in PLP.
Both Nikolajsen and Smith’s gabapentin studies used the SF-MPQ, and did not report a
significant decrease in PLP (Nikolajsen et al., 2006; Smith et al., 2005). The 10 cm VAS was
used in Huse’s morphine study, where a significant decrease in PLP was reported (Huse et al.,
2001). Kumar’s case study of morphine also used the 10 cm VAS, where the patient’s initial pain
rating was an 8. With continued morphine treatment, his pain was reduced to lower than a 4
(Kumar et al., 2015). Bone and Wu’s studies of gabapentin and morphine, respectively, analyzed
pain with the 100 cm VAS. Bone’s study did not show a significant decrease in PLP, while Wu’s
study reported a significant PLP decrease (Bone, 2002; Wu et al., 2002).
Analyzing these studies as a whole, MT has shown to provide a consistent decrease in
PLP across the five studies. While there have been morphine and gabapentin studies that have
shown a significant decrease in PLP, there are inconsistencies among them. The three morphine
studies show a decrease in PLP, while the gabapentin studies show no significant change,
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however, one shows a meaningful decrease in pain. The MT studies consistently show a decrease
in PLP. This discrepancy, however, could be due to the fact that there are less studies on
pharmaceuticals in regards to treating PLP, while MT has been studied to a greater extent.
It is important to understand that there are more MT studies, however, for the purposes of
this literature review, five studies were further analyzed and discussed. In recent years, studies
have come out regarding the use of virtual reality systems for the alleviation of PLP, which acts
in a similar manner to MT. One such study was performed by Coleman et al. in 2009, where
participants were wired to a virtual reality system, and asked to perform tasks with their phantom
limb, which was represented on the screen. It was reported that PLP reduction ranged from 22%
to 100% (Cole et al., 2009). Statistical significance was not reported, as more data on the use of
virtual reality is necessary in order to best understand its effects.

Risks and Side Effects
While mirror therapy (MT) and pharmacological intervention are often used to alleviate
PLP, they do not come without risks and side effects. The side effects of using MT, while
relatively low, include confusion and dizziness due to continually looking at the mirror and
relating it to the phantom limb movement. MT can, in some individuals, cause an increase in
PLP, and a heightening of movement disorders (Wittkopf & Johnson, 2017). MT has a smaller
side effect profile than gabapentin and morphine, however, the patients must still be closely
monitored in order to determine the best course of treatment moving forward.
Morphine comes with a higher risk profile. The most common side effects are
drowsiness, dizziness, headache, and stomach pain. More severe side effects include difficulty
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breathing, nausea and vomiting, constipation, or even seizures (“Morphine: Strong Painkiller,”
2018; “Morphine,” 2021). Morphine is a Schedule II drug, which means that its use is highly
regulated in the medical field, as it is highly addictive. Even taking morphine as prescribed can
pose an addiction risk, as the body can become dependent on the drug, leading to abuse and
addiction (Hardey et al., 2020).
Gabapentin has a similar side effect profile to morphine. The most common ones are
dizziness, headache, constipation, drowsiness, and anxiety. More severe side effects include
seizures, difficulty breathing, and facial swelling (Yasaei, 2021). Gabapentin is also associated
with an increased risk of depression and suicidal thoughts or actions (“Gapapentin (Oral Route),”
2021). The addiction risk of gabapentin is less than that of morphine, but is still a risk. It is more
likely to create a psychological dependence to the high it produces, rather than a physical
dependence (Hardey, 2021).
Constant monitoring of the patient using any type of PLP treatment is necessary in order
to ensure the best outcome.

Limitations
While these studies provide significant information about the efficacy of both MT and
pharmaceuticals, there are limitations to them. Many of the studies had a limited number of
participants, reducing the integrity of the results. Additionally, with the pharmaceutical
treatments, some of the effects could have been altered due to the “carry-over effects” from one
treatment phase to another (Wu, 2002). There were only washout phases implemented in the
Smith and Bone studies, with a five-week and one-week washout period where no drug was
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administered, respectively (Smith, et al., 2005; Bone 2002). Wu and Huse’s studies did not
perform washout phases, which could have caused the “carry-ever effects” (Wu, 2002).
There are a limited number of studies regarding the efficacy of pharmaceuticals when
treating PLP. While the limited number of studies on gabapentin and morphine show a mix of
results, it does not mean that there is nothing to conclude about these drugs in regards to PLP.
More double-blind crossover studies with a greater number of participants would allow more
concrete results to be collected, and provide a better understanding of what treatments would
best suit a person struggling with PLP.

Conclusions
Phantom limb pain (PLP) is a debilitating phenomenon that many amputees struggle with
everyday. Over the last two decades there have been many new studies published examining the
etiology and possible treatments for PLP. Two of the most common treatments are mirror therapy
(MT) and pharmaceuticals. In this review, morphine and gabapentin were the two
pharmaceuticals examined. While mirror therapy may work for one amputee, it may not work for
another, or even exacerbate the pain (Wittkopf & Johnson, 2017). Additionally, gabapentin does
not work, and morphine may not work in providing alleviation for PLP. It is important to
understand the efficacy of both MT and pharmaceuticals in order to best treat someone
struggling with PLP. While there have been more studies published regarding the treatment of
PLP, there is still a gap in the research. There is a lack of comparison of two of the major
treatments of PLP, those being mirror therapy and pharmaceuticals. This review begins to fill in
that gap by comparing the efficacy of these two treatments.
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MT provided the most consistent results, showing alleviation of PLP across all five
studies. Four of the studies showed a numerical decrease in pain ratings using both the visual
analogue scale and the Short Form McGill Pain Questionnaire. Based on the findings of this
review, MT appears to be the best first line treatment, due to its more consistent reduction of pain
and reduced side effects. However, MT may need to be supplemented or even replaced with
morphine or gabapentin in patients who do not receive adequate pain relief from MT. As more
data is collected on pharmaceuticals and their effect on PLP, better judgments can be made
regarding the best treatment plan for PLP.

28
References
Alviar MJ, Hale T, Dungca M. (2016). Pharmacologic interventions for treating phantom limb
pain. Cochrane Database Syst Rev. 2016;10(10):CD006380.
doi:10.1002/14651858.CD006380.pub3
Amputee Coalition. (2017). Limb Loss Statistics. Amputee Coalition.
https://www.amputee-coalition.org/resources/limb-loss-statistics/
Anderson-Barnes, V. C., McAuliffe, C., Swanberg, K. M., & Tsao, J. W. (2009). Phantom limb
pain – A phenomenon of proprioceptive memory? Medical Hypotheses, 73(4), 555–558.
https://doi.org/10.1016/j.mehy.2009.05.038
Andoh, J., Milde, C., Tsao, J. W., & Flor, H. (2018). Cortical plasticity as a basis of phantom
limb pain: Fact of fiction?. Science Direct. 387.
https://doi.org/10.1016/j.neuroscience.2017.11.015
Balakhanlou, E., Webster, J., Borgia, M., & Resnik, L. (2021). Frequency and severity of
phantom limb pain in veterans with major upper limb amputation: Results of a national
survey. PM&R, 13(8), 827–835. https://doi.org/10.1002/pmrj.12485
Bone, M., Critchley, P., & Buggy, D. J. (2002). Gabapentin in postamputation phantom limb
pain: A randomized, double-blind, placebo-controlled, cross-over study. Regional
Anesthesia and Pain Medicine, 27(5), 481–486. https://doi.org/10.1053/rapm.2002.35169
Cole, J., Crowle, S., Austwick, G., & Henderson Slater, D. (2009). Exploratory findings with
virtual reality for phantom limb pain; from stump motion to agency and analgesia.
Disability and Rehabilitation, 31(10), 846–854.
https://doi.org/10.1080/09638280802355197
Collins, K. L., Russell, H. G., Schumacher, P. J., Robinson-Freeman, K. E., O'Conor, E. C.,
Gibney, K. D., Yambem, O., Dykes, R. W., Waters, R. S., & Tsao, J. W. (2018). A review
of current theories and treatments for phantom limb pain. The Journal of clinical
investigation, 128(6), 2168–2176. https://doi.org/10.1172/JCI94003
Dijkstra, P. U., Geertzen, J. H. B., Stewart, R., & van der Schans, C. P. (2002). Phantom pain and
risk factors: A multivariate analysis. Journal of Pain and Symptom Management, 24(6),
578–585. https://doi.org/10.1016/S0885-3924(02)00538-9
Fig. 1. The visual analogue scale (Vas) used for evaluating the... (n.d.). ResearchGate. Retrieved
December 15, 2021, from

29
https://www.researchgate.net/figure/The-visual-analogue-scale-VAS-used-for-evaluatingthe-perceived-pain-among-patients_fig1_330139149
Finn, S. B., Perry, B. N., Clasing, J. E., Walters, L. S., Jarzombek, S. L., Curran, S., Rouhanian,
M., Keszler, M. S., Hussey-Andersen, L. K., Weeks, S. R., Pasquina, P. F., & Tsao, J. W.
(2017). A randomized, controlled trial of mirror therapy for upper extremity phantom
limb pain in male amputees. Frontiers in Neurology, 8, 267.
https://doi.org/10.3389/fneur.2017.00267
Flor, H., Elbert, T., Muhlnickel, W., Pantev, C., Wienbruch, C., & Taub, E. (1998). Cortical
reorganization and phantom phenomena in congenital and traumatic upper-extremity
amputees. Experimental Brain Research, 119(2), 205+.
https://link.gale.com/apps/doc/A301774129/PPNU?u=mlin_c_assumpt&sid=bookmark-P
PNU&xid=21ad7af8
Foell, J., Bekrater-Bodmann, R., Diers, M., & Flor, H. (2014). Mirror therapy for phantom limb
pain: Brain changes and the role of body representation. European Journal of Pain,
18(5), 729–739. https://doi.org/10.1002/j.1532-2149.2013.00433.x
Gabapentin (Oral route) side effects—Mayo clinic. (n.d.). Retrieved December 15, 2021, from
https://www.mayoclinic.org/drugs-supplements/gabapentin-oral-route/side-effects/drg-20
064011?p=1
Genetic Science Learning Center. (2014). Proprioception: Additional Information. Retrieved
December 13, 2021, from https://learn.genetics.utah.edu/content/senses/proprioception/
Gentili, M. E., Verton, C., Kinirons, B., & Bonnet, F. (2002). Clinical perception of phantom
limb sensation in patients with brachial plexus block. European journal of
anaesthesiology, 19(2), 105-108.
Grens, K. (2014). Pain and progress. The Scientist Magazine®.
https://www.the-scientist.com/cover-story/pain-and-progress-38043
Griffin, S. C., Curran, S., Chan, A. W. Y., Finn, S. B., Baker, C. I., Pasquina, P. F., & Tsao, J. W.
(2017). Trajectory of phantom limb pain relief using mirror therapy: Retrospective
analysis of two studies. Scandinavian Journal of Pain, 15(1), 98–103.
https://doi.org/10.1016/j.sjpain.2017.01.007
Guenther, K. (2016). ‘It’s All Done With Mirrors’: V.S. Ramachandran and the Material Culture
of Phantom Limb Research. Medical History, 60(3), 342-358. doi:10.1017/mdh.2016.27

30
Hanling, S., Wallace, S., Hollenbeck, K. J., Belnap, B., & Tulis, M. R. (2010). Preamputation
mirror therapy may prevent development of phantom limb pain: A case series. Undefined.
https://www.semanticscholar.org/paper/Preamputation-mirror-therapy-may-prevent-of-ph
antom-Hanling-Wallace/1706c4828c57442607d78eaf9c5425fd7fea23a7/figure/2
Hardey, S., Thomas, S., Stein, S., Kelley, R., & Ackermann, K. (2020). How addictive is
morphine, an opiate? American Addiction Centers.
https://americanaddictioncenters.org/morphine-treatment/how-addictive
Hardey, S., Thomas, S., Stein, S., Kelley, R., & Ackermann, K. (2021). Is neurontin
(Gabapentin) abused? . American Addiction Centers.
https://americanaddictioncenters.org/neurontin-abuse
Huse, E., Larbig, W., Flor, H., & Birbaumer, N. (2001). The effect of opioids on phantom limb
pain and cortical reorganization. Pain, 90(1), 47–55.
https://doi.org/10.1016/S0304-3959(00)00385-7
Kuffler, D. P. (2018). Origins of phantom limb pain. Molecular Neurobiology, 55(1), 60–69.
https://doi.org/10.1007/s12035-017-0717-x
Kumar, V., Garg, R., Bharati, S. J., Gupta, N., Bhatanagar, S., Mishra, S., & Balhara, Y. P. S.
(2015). Long-term high-dose oral morphine in phantom limb pain with no addiction risk.
Indian Journal of Palliative Care, 21(1), 85–87.
https://doi.org/10.4103/0973-1075.150198
Mcgill pain questionnaire. (n.d.). Shirley Ryan AbilityLab. Retrieved December 15, 2021, from
https://www.sralab.org/rehabilitation-measures/mcgill-pain-questionnaire
Morphine: Medlineplus drug information. (n.d.). Retrieved December 15, 2021, from
https://medlineplus.gov/druginfo/meds/a682133.html
Morphine: Strong painkiller to treat severe pain. (2018). Nhs.Uk.
https://www.nhs.uk/medicines/morphine/
Morphine Sulfate 10 mg/ml solution for injection—Summary of Product Characteristics
(Smpc)—(Emc). (n.d.). Retrieved December 15, 2021, from
https://www.medicines.org.uk/emc/product/6426/smpc#gref

31
Murphy, P. B., Bechmann, S., & Barrett, M. J. (2021). Morphine. In StatPearls. StatPearls
Publishing. http://www.ncbi.nlm.nih.gov/books/NBK526115/
National Research Council (US) and Institute of Medicine (US) Committee on the Mathematics
and Physics of Emerging Dynamic Biomedical Imaging. Mathematics and Physics of
Emerging Biomedical Imaging. Washington (DC): National Academies Press (US).
(1996). Chapter 10, Magnetic Source Imaging. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK232481/
Nguyen, J. D., & Duong, H. (2021). Neurosurgery, sensory homunculus. In StatPearls.
StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK549841/
Niere, K. (2009). Chapter 13—Measurement of headache. In P. Selvaratnam, K. Niere, M.
Zuluaga, S. Friedmann, C. Sloan, & E. Byrne (Eds.), Headache, Orofacial Pain and
Bruxism (pp. 153–165). Churchill Livingstone.
https://doi.org/10.1016/B978-0-443-10310-0.00013-7
Nikolajsen, L., & Christensen, K. F. (2015). Chapter 2—Phantom limb pain. In R. S. Tubbs, E.
Rizk, M. M. Shoja, M. Loukas, N. Barbaro, & R. J. Spinner (Eds.), Nerves and Nerve
Injuries (pp. 23–34). Academic Press.
https://doi.org/10.1016/B978-0-12-802653-3.00051-8
Nikolajsen, L., Finnerup, N. B., Kramp, S., Vimtrup, A.-S., Keller, J., & Jensen, T. S. (2006). A
randomized study of the effects of gabapentin on postamputation pain. Anesthesiology,
105(5), 1008–1015. https://doi.org/10.1097/00000542-200611000-00023
Phantom pain—Diagnosis and treatment—Mayo clinic. (n.d.). Retrieved December 14, 2021,
from
https://www.mayoclinic.org/diseases-conditions/phantom-pain/diagnosis-treatment/drc-2
0376278
Phantom pain—Symptoms and causes—Mayo clinic. (n.d.). Retrieved December 7, 2021, from
https://www.mayoclinic.org/diseases-conditions/phantom-pain/symptoms-causes/syc-203
76272
Ramachandran, V., & Hirstein, W. (1998). The perception of phantom limbs. The D. O. Hebb
lecture. Brain, 121(9), 1603–1630. https://doi.org/10.1093/brain/121.9.1603

32
Ramachandran, V. S., & Rogers-Ramachandran, D. (1996). Synaesthesia in phantom limbs
induced with mirrors. Proceedings of the Royal Society of London. Series B: Biological
Sciences, 263(1369), 377–386. https://doi.org/10.1098/rspb.1996.0058
Ramachandran, V. S., Rogers-Ramachandran, D., & Cobb, S. (1995). Touching the phantom
limb. Nature, 377(6549), 489–490. https://doi.org/10.1038/377489a0
Ramadugu, S., Nagabushnam, S. C., Katuwal, N., & Chatterjee, K. (2017). Intervention for
phantom limb pain: A randomized single crossover study of mirror therapy. Indian
Journal of Psychiatry, 59(4), 457–464.
https://doi.org/10.4103/psychiatry.IndianJPsychiatry_259_16
Rawlence, C. (Director). (2001). Secrets of the Mind [Film]. NOVA.
Short-form mcgill pain questionnaire. (n.d.). Physiopedia. Retrieved December 9, 2021, from
https://www.physio-pedia.com/Short-form_McGill_Pain_Questionnaire
Smith, D. G., Ehde, D. M., Hanley, M. A., Campbell, K. M., Jensen, M. P., Hoffman, A. J.,
Awan, A. B., Czerniecki, J. M., & Robinson, L. R. (2005). Efficacy of gabapentin in
treating chronic phantom limb and residual limb pain. Journal of Rehabilitation Research
and Development, 42(5), 645–654. https://doi.org/10.1682/jrrd.2005.05.0082
Subedi, B., & Grossberg, G. T. (2011). Phantom limb pain: mechanisms and treatment
approaches. Pain research and treatment, 2011, 864605.
https://doi.org/10.1155/2011/864605
Trevelyan, E. G., Turner, W. A., & Robinson, N. (2016). Perceptions of phantom limb pain in
lower limb amputees and its effect on quality of life: a qualitative study. British Journal
of Pain, 10(2), 70–77. https://doi.org/10.1177/2049463715590884
Visual analogue scale | Yale assessment module training. (n.d.). Retrieved December 15, 2021,
from https://assessment-module.yale.edu/im-palliative/visual-analogue-scale
Wittkopf, P. G., & Johnson, M. I. (2017). Mirror therapy: A potential intervention for pain
management. Revista Da Associacao Medica Brasileira (1992), 63(11), 1000–1005.
https://doi.org/10.1590/1806-9282.63.11.1000
What are the signs someone is addicted to gabapentin? (2020). Addiction Treatment Center
Cornerstone of Recovery.
https://www.cornerstoneofrecovery.com/what-are-the-signs-someone-is-addicted-to-gaba
pentin/

33
What are opioids? - Made for this moment. (n.d.). Made For This Moment | Anesthesia, Pain
Management & Surgery. Retrieved December 15, 2021, from
https://www.asahq.org/madeforthismoment/pain-management/opioid-treatment/what-areopioids/
What is MSI? (n.d.). Retrieved December 14, 2021, from
http://uuhsc.utah.edu/uumsi/what-is-msi.html
Wu, C. L., Tella, P., Staats, P. S., Vaslav, R., Kazim, D. A., Wesselmann, U., & Raja, S. N.
(2002). Analgesic effects of intravenous lidocaine and morphine on postamputation pain:
A randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology,
96(4), 841–848. https://doi.org/10.1097/00000542-200204000-00010
Yasaei, R., Katta, S., & Saadabadi, A. (2021). Gabapentin. In StatPearls. StatPearls Publishing.
http://www.ncbi.nlm.nih.gov/books/NBK493228/

